Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 27, 2025 08:30 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing

Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc (“JUNS” or the...
August 26, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements

Targeting the Multi-Trillion Dollar Longevity Market Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage...
August 19, 2025 08:12 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador

Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Jupiter...
August 11, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience

MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) --...
July 23, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the...
July 10, 2025 16:05 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nasdaq compliance follows positive upward trend in Company’s Stock Price Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the...
June 30, 2025 15:15 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter...
June 23, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, June 23, 2025 (GLOBE NEWSWIRE) -- Jupiter...
June 09, 2025 07:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science

First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter...
April 08, 2025 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter

Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL™ JOTROL™ development programs remain tariff-exempt; consumer...